Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Advanced Malignancy: A Phase Ib Trial
Ronald G. Steis, Walter J. Urba(Providence Portland Medical Center), J. Hursey(Calvert Memorial Hospital), Stephen P. Creekmore(Bryan College), Jeffrey W. Clark(Massachusetts General Hospital), William C. Kopp(Frederick National Laboratory for Cancer Research), J. W. Smith(Frederick National Laboratory for Cancer Research), DL Longo(Frederick National Laboratory for Cancer Research), L J Elwood(National Cancer Institute), Francis W. Ruscetti(Frederick National Laboratory for Cancer Research), L. A. VANDERMOLEN(Frederick National Laboratory for Cancer Research)
Cited by 40
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
|Journal of Clinical Oncology|2012|1.6k